Total Payments
$450,470
2024 Payments
$44,462
Companies
36
Transactions
827
Medicare Patients
5,583
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$341,595 (75.8%)
Travel$60,464 (13.4%)
Consulting$30,361 (6.7%)
Food & Beverage$17,670 (3.9%)
Education$379.81 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $318,170 | 163 | 70.6% |
| Travel and Lodging | $60,464 | 255 | 13.4% |
| Consulting Fee | $30,361 | 19 | 6.7% |
| Food and Beverage | $17,670 | 371 | 3.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $14,125 | 5 | 3.1% |
| Honoraria | $9,300 | 4 | 2.1% |
| Education | $379.81 | 10 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $138,893 | 163 | $0 (2024) |
| Allergan, Inc. | $74,897 | 173 | $0 (2020) |
| Astellas Pharma US Inc | $69,222 | 94 | $0 (2024) |
| Genentech USA, Inc. | $43,343 | 46 | $0 (2021) |
| Merck Sharp & Dohme LLC | $37,540 | 68 | $0 (2023) |
| Insmed, Inc. | $21,139 | 77 | $0 (2024) |
| Shionogi Inc | $18,375 | 30 | $0 (2024) |
| ABBVIE INC. | $12,474 | 36 | $0 (2024) |
| Melinta Therapeutics, LLC | $10,948 | 24 | $0 (2024) |
| BioFire Diagnostics, LLC | $6,000 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,462 | 79 | Takeda Pharmaceuticals U.S.A., Inc. ($29,139) |
| 2023 | $142,486 | 184 | Takeda Pharmaceuticals U.S.A., Inc. ($108,500) |
| 2022 | $14,070 | 52 | ABBVIE INC. ($3,115) |
| 2021 | $22,591 | 63 | Genentech USA, Inc. ($15,960) |
| 2020 | $46,848 | 86 | Genentech USA, Inc. ($16,321) |
| 2019 | $70,872 | 146 | Astellas Pharma US Inc ($17,336) |
| 2018 | $59,152 | 106 | Allergan Inc. ($29,696) |
| 2017 | $49,988 | 111 | Allergan Inc. ($18,387) |
All Payment Transactions
827 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: Respiratory | ||||||
| 12/19/2024 | Invivyd Inc | PEMGARDA (Biological) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/19/2024 | Invivyd Inc | PEMGARDA (Biological) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/04/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: ANTIFUNGALS | ||||||
| 11/22/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/20/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: ANTIBIOTIC | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,830.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,830.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Travel and Lodging | In-kind items and services | $445.54 | General |
| Category: IMMUNOLOGY | ||||||
| 11/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Travel and Lodging | In-kind items and services | $28.14 | General |
| Category: IMMUNOLOGY | ||||||
| 11/02/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: Respiratory | ||||||
| 10/27/2024 | KAMADA LTD. | CYTOGAM (Drug) | Food and Beverage | Cash or cash equivalent | $25.19 | General |
| Category: Infectious Disease | ||||||
| 10/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Travel and Lodging | In-kind items and services | $443.02 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Travel and Lodging | In-kind items and services | $430.63 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $32.16 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/22/2024 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $32.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/22/2024 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Travel and Lodging | In-kind items and services | $1,262.43 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Travel and Lodging | In-kind items and services | $438.38 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $75.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/15/2024 | Shionogi Inc | Fetroja (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $4,545.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/10/2024 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $675.50 | General |
| Category: Infections and Infectious Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,062 | 14,840 | $1.3M | $361,338 |
| 2022 | 19 | 1,309 | 96,679 | $1.5M | $426,421 |
| 2021 | 23 | 1,547 | 118,366 | $2.6M | $612,787 |
| 2020 | 26 | 1,665 | 76,649 | $2.1M | $482,692 |
Total Patients
5,583
Total Services
306,534
Medicare Billing
$1.9M
Procedure Codes
85
All Medicare Procedures & Services
85 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 19 | 11,100 | $477,625 | $130,106 | 27.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 210 | 884 | $221,000 | $54,851 | 24.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 101 | 479 | $108,819 | $44,458 | 40.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 190 | 362 | $81,378 | $34,724 | 42.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 71 | 671 | $107,380 | $33,316 | 31.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 124 | 127 | $37,755 | $12,935 | 34.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 91 | 94 | $40,757 | $12,826 | 31.5% |
| 36573 | Insertion of tube for infusion with imaging guidance and review by radiologist, patient 5 years or older | Office | 2023 | 26 | 28 | $16,800 | $8,450 | 50.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 42 | 42 | $14,651 | $5,362 | 36.6% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 16 | 504 | $165,284 | $5,248 | 3.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 24 | 331 | $16,700 | $5,233 | 31.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 62 | $9,193 | $4,078 | 44.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 27 | $8,216 | $3,778 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $7,880 | $2,912 | 37.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 20 | 40 | $3,560 | $1,545 | 43.4% |
| 36592 | Collection of blood sample from central venous tube | Office | 2023 | 17 | 51 | $2,805 | $1,155 | 41.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 16 | 20 | $1,200 | $360.40 | 30.0% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 25 | 14,100 | $593,656 | $166,773 | 28.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 150 | 638 | $144,941 | $52,133 | 36.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 241 | 912 | $228,000 | $51,190 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 219 | 429 | $96,439 | $42,406 | 44.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 74 | 559 | $89,560 | $29,965 | 33.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 162 | 179 | $77,665 | $28,203 | 36.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 132 | 137 | $40,855 | $14,751 | 36.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 77 | 99 | $14,680 | $6,835 | 46.6% |
About Dr. Cedric Spak, MD
Dr. Cedric Spak, MD is a Infectious Disease healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063575199.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cedric Spak, MD has received a total of $450,470 in payments from pharmaceutical and medical device companies, with $44,462 received in 2024. These payments were reported across 827 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($318,170).
As a Medicare-enrolled provider, Spak has provided services to 5,583 Medicare beneficiaries, totaling 306,534 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 85 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Fort Worth, TX
- Active Since 12/19/2006
- Last Updated 10/29/2018
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1063575199
Products in Payments
- LIVTENCITY (Drug) $137,213
- Xofluza (Drug) $43,343
- DALVANCE (Drug) $41,884
- AVYCAZ (Drug) $39,657
- CRESEMBA (Drug) $28,798
- ZERBAXA (Drug) $22,691
- Cresemba (Drug) $21,319
- Arikayce (Drug) $20,749
- Fetroja (Drug) $17,867
- DIFICID (Drug) $9,066
- Kimyrsa (Drug) $6,139
- BioFire FilmArray (Device) $6,000
- TEFLARO (Drug) $5,629
- Orbactiv (Drug) $4,631
- PEMGARDA (Biological) $3,695
- ORBACTIV (Drug) $3,479
- RECARBRIO (Drug) $2,991
- ZEMDRI (PLAZOMICIN) (Drug) $1,095
- DOVATO (Drug) $370.22
- CYTOGAM (Drug) $313.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Fort Worth
Cheryl Mcdonald, M.d, M.D
Infectious Disease — Payments: $214,900
Infectious Disease $214,900
Daniel Barbaro, M.d, M.D
Infectious Disease — Payments: $74,179
Infectious Disease $74,179
Mark Hupert, M.d, M.D
Infectious Disease — Payments: $10,107
Infectious Disease $10,107
Dr. Steven Sotman, M.d, M.D
Infectious Disease — Payments: $4,353
Infectious Disease $4,353
Dr. Vitaly Golub, Md, MD
Infectious Disease — Payments: $4,211
Infectious Disease $4,211
Allan Kelly, M.d, M.D
Infectious Disease — Payments: $2,713
Infectious Disease $2,713